{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T11:26:20Z","timestamp":1791890780307,"version":"4.3.4"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T00:00:00Z","timestamp":1692316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T00:00:00Z","timestamp":1692316800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81960130"],"award-info":[{"award-number":["81960130"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Genomics"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Alport syndrome (AS; OMIM#308,940) is a hereditary kidney disease that progresses over time and is distinguished by hearing loss and ocular irregularities. The syndrome has three subtypes, namely X-linked (XL; OMIM#301,050), autosomal recessive (AR; OMIM#203,780), and autosomal dominant (AD; OMIM#104,200), which are categorized based on their respective modes of inheritance. XLAS is attributed to a pathogenic variant in the\n                      <jats:italic>COL4A5<\/jats:italic>\n                      (OMIM*303,630) gene, which encodes the \u03b15(IV) chain of type IV collagen (Col-IV). In contrast, ADAS and ARAS are the result of variants in the\n                      <jats:italic>COL4A3<\/jats:italic>\n                      (OMIM*120,070) and\n                      <jats:italic>COL4A4<\/jats:italic>\n                      (OMIM*120,131) genes, which encode the \u03b13(IV) and \u03b14(IV) chains of Col-IV, respectively. Typically, the diagnosis of AS necessitates hereditary or pathological assessments. The determination of splicing variants as pathogenic or non-pathogenic based on gene sequencing outcomes is challenging.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In this study, we conducted exome sequencing and Sanger sequencing on two unrelated Chinese patients with AS. We identified a deletion variant c.4414delG in the\n                      <jats:italic>COL4A5<\/jats:italic>\n                      gene and a splicing variant c.4298-20T\u2009&gt;\u2009A in the same gene. In order to ascertain the impact of c.4298-20T\u2009&gt;\u2009A on the synthesis of\n                      <jats:italic>COL4A5<\/jats:italic>\n                      mRNA, we performed experiments involving minigene splicing. Additionally, we predicted the ability of these two variants to affect triple helix formation of \u03b1345(IV) using molecular dynamics methods.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The c.4414delG deletion variant caused a change in the genetic code of the\n                      <jats:italic>COL4A5<\/jats:italic>\n                      gene. Specifically, it caused a shift in codon 1472 from encoding aspartate to encoding methionine. This shift resulted in a change of 75 amino acids in the protein sequence, ultimately leading to an early stop codon. This premature stop codon caused the production of a truncated \u03b15(IV) chain with a predicted protein effect of p.D1472Mfs. The mRNA of the\n                      <jats:italic>COL4A5<\/jats:italic>\n                      gene experienced intron 46 retention due to the splicing variant c.4298-20T\u2009&gt;\u2009A, leading to the inclusion of six additional amino acids between amino acids 1432 and 1433 of the \u03b15(IV) chain. This variant is predicted to have a protein effect of p.(P1432_G1433insDYFVEI). The impact of two variants, c.4414delG and c.4298-20T\u2009&gt;\u2009A, on the aggregation region for \u03b13(IV), \u03b14(IV), and \u03b15(IV) trimerisation were studied using molecular dynamics simulations. Results showed that the deletion variant c.4414delG had a significantly stronger disruption on NC1, compared to the splicing variant c.4298-20T\u2009&gt;\u2009A. This difference in impact is consistent with the varying clinical phenotypes observed in the two patients. Based on the American College of Medical Genetics and Genomics (ACMG) classification criteria and guidelines for genetic variants, the deletion variant c.4414delG was rated as pathogenic while the splicing variant c.4298-20T\u2009&gt;\u2009A was rated as likely-pathogenic.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our study has identified two novel pathogenic loci, the deletion variant c.4414delG and the splicing variant c.4298-20T\u2009&gt;\u2009A, associated with XLAS. This finding expands the genetic spectrum of XLAS. We suggest that molecular dynamics can effectively model the effect of genetic variation on \u03b1345(IV) trimerization, which may offer valuable insights into the mechanisms of XLAS pathogenesis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12920-023-01623-7","type":"journal-article","created":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T03:03:10Z","timestamp":1692327790000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Genetic and molecular dynamics analysis of two variants of the COL4A5 gene causing Alport syndrome"],"prefix":"10.1186","volume":"16","author":[{"given":"Lei","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haotian","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeyu","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianrong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,18]]},"reference":[{"issue":"25","key":"1623_CR1","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1056\/NEJMra022296","volume":"348","author":"BG Hudson","year":"2003","unstructured":"Hudson BG, Tryggvason K, Sundaramoorthy M, Neilson EG. Alport\u2019s syndrome, Goodpasture\u2019s syndrome, and type IV collagen. N Engl J Med. 2003;348(25):2543\u201356. https:\/\/doi.org\/10.1056\/NEJMra022296.","journal-title":"N Engl J Med"},{"key":"1623_CR2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.matbio.2016.08.005","volume":"57\u201358","author":"D Cosgrove","year":"2017","unstructured":"Cosgrove D, Liu S. Collagen IV diseases: a focus on the glomerular basement membrane in Alport syndrome. Matrix Biol. 2017;57\u201358:45\u201354. https:\/\/doi.org\/10.1016\/j.matbio.2016.08.005.","journal-title":"Matrix Biol"},{"key":"1623_CR3","doi-asserted-by":"publisher","unstructured":"Gross O, Kashtan CE, Rheault MN, Flinter F, Savige J, Miner JH et al. (2017). Advances and unmet needs in genetic, basic and clinical science in Alport syndrome: report from the 2015 International Workshop on Alport Syndrome. Nephrol. Dial. Transplant 32(6), 916\u2013924. https:\/\/doi.org\/10.1093\/ndt\/gfw095.","DOI":"10.1093\/ndt\/gfw095"},{"issue":"2","key":"1623_CR4","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1007\/s10157-018-1629-4","volume":"23","author":"K Nozu","year":"2019","unstructured":"Nozu K, Nakanishi K, Abe Y, Udagawa T, Okada S, Okamoto T, et al. A review of clinical characteristics and genetic backgrounds in Alport syndrome. Clin Exp Nephrol. 2019;23(2):158\u201368. https:\/\/doi.org\/10.1007\/s10157-018-1629-4.","journal-title":"Clin Exp Nephrol"},{"issue":"12","key":"1623_CR5","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1681\/ASN.2013080912","volume":"25","author":"V Morini\u00e8re","year":"2014","unstructured":"Morini\u00e8re V, Dahan K, Hilbert P, Lison M, Lebbah S, Topa A, et al. Improving mutation screening in familial hematuric nephropathies through next generation sequencing. J Am Soc Nephrol. 2014;25(12):2740\u201351. https:\/\/doi.org\/10.1681\/ASN.2013080912.","journal-title":"J Am Soc Nephrol"},{"issue":"4","key":"1623_CR6","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1681\/ASN.V114649","volume":"11","author":"JP Jais","year":"2000","unstructured":"Jais JP, Knebelmann B, Giatras I, Marchi M, Rizzoni G, Renieri A, et al. X-linked Alport syndrome: natural history in 195 families and genotype- phenotype correlations in males. J Am Soc Nephrol. 2000;11(4):649\u201357. https:\/\/doi.org\/10.1681\/ASN.V114649.","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"1623_CR7","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1681\/ASN.2009070784","volume":"21","author":"MR Bekheirnia","year":"2010","unstructured":"Bekheirnia MR, Reed B, Gregory MC, McFann K, Shamshirsaz AA, Masoumi A, et al. Genotype-phenotype correlation in X-linked Alport syndrome. J Am Soc Nephrol. 2010;21(5):876\u201383. https:\/\/doi.org\/10.1681\/ASN.2009070784.","journal-title":"J Am Soc Nephrol"},{"issue":"7","key":"1623_CR8","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1093\/ndt\/17.7.1218","volume":"17","author":"O Gross","year":"2002","unstructured":"Gross O, Netzer KO, Lambrecht R, Seibold S, Weber M. Meta-analysis of genotype-phenotype correlation in X-linked Alport syndrome: impact on clinical counselling. Nephrol Dial Transplant. 2002;17(7):1218\u201327. https:\/\/doi.org\/10.1093\/ndt\/17.7.1218.","journal-title":"Nephrol Dial Transplant"},{"key":"1623_CR9","doi-asserted-by":"publisher","unstructured":"Gong WY, Liu FN, Yin LH, Zhang J. (2021). Novel Mutations of COL4A5 Identified in Chinese Families with X-Linked Alport Syndrome and Literature Review. Biomed. Res. Int 2021, 6664973. https:\/\/doi.org\/10.1155\/2021\/6664973.","DOI":"10.1155\/2021\/6664973"},{"issue":"5","key":"1623_CR10","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","volume":"17","author":"S Richards","year":"2015","unstructured":"Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405\u201324. https:\/\/doi.org\/10.1038\/gim.2015.30.","journal-title":"Genet Med"},{"key":"1623_CR11","doi-asserted-by":"publisher","unstructured":"Demosthenous P, Voskarides K, Stylianou K, Hadjigavriel M, Arsali M, Patsias C et al. X-linked Alport syndrome in Hellenic families: phenotypic heterogeneity and mutations near interruptions of the collagen domain in COL4A5. Clin Genet 81(3), 240\u20138. https:\/\/doi.org\/10.1111\/j.1399-0004.2011.01647.x.","DOI":"10.1111\/j.1399-0004.2011.01647.x"},{"issue":"12","key":"1623_CR12","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1038\/sj.ki.5002221","volume":"71","author":"M Slajpah","year":"2007","unstructured":"Slajpah M, Gorinsek B, Berginc G, Vizjak A, Ferluga D, et al. Sixteen novel mutations identified in COL4A3, COL4A4, and COL4A5 genes in slovenian families with Alport syndrome and benign familial hematuria. Kidney Int. 2007;71(12):1287\u201395. https:\/\/doi.org\/10.1038\/sj.ki.5002221.","journal-title":"Kidney Int"},{"issue":"5","key":"1623_CR13","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1038\/ki.2013.479","volume":"85","author":"Y Hashimura","year":"2014","unstructured":"Hashimura Y, Nozu K, Kaito H, Nakanishi K, Fu XJ, Ohtsubo H, et al. Milder clinical aspects of X-linked Alport syndrome in men positive for the collagen IV alpha5 chain. Kidney Int. 2014;85(5):1208\u201313. https:\/\/doi.org\/10.1038\/ki.2013.479.","journal-title":"Kidney Int"},{"issue":"5","key":"1623_CR14","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s10157-015-1197-9","volume":"20","author":"XJ Fu","year":"2016","unstructured":"Fu XJ, Nozu K, Eguchi A, Nozu Y, Morisada N, Shono A, et al. X-linked Alport syndrome associated with a synonymous p.Gly292Gly mutation alters the splicing donor site of the type IV collagen alpha chain 5 gene. Clin Exp Nephrol. 2016;20(5):699\u2013702. https:\/\/doi.org\/10.1007\/s10157-015-1197-9.","journal-title":"Clin Exp Nephrol"},{"key":"1623_CR15","doi-asserted-by":"publisher","unstructured":"Horinouchi T, Yamamura T, Minamikawa S, Nagano C, Sakakibara N, Nakanishi K, et al. Pathogenic evaluation of synonymous COL4A5 variants in X-linked Alport syndrome using a minigene assay. Mol Genet Genomic Med. 2020;8(8). https:\/\/doi.org\/10.1002\/mgg3.1342. e1342.","DOI":"10.1002\/mgg3.1342"},{"issue":"1","key":"1623_CR16","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s00441-009-0866-y","volume":"339","author":"T Van Agtmael","year":"2010","unstructured":"Van Agtmael T, Bruckner-Tuderman L. Basement membranes and human disease. Cell Tissue Res. 2010;339(1):167\u201388. https:\/\/doi.org\/10.1007\/s00441-009-0866-y.","journal-title":"Cell Tissue Res"},{"issue":"50","key":"1623_CR17","doi-asserted-by":"publisher","first-page":"38117","DOI":"10.1074\/jbc.R600025200","volume":"281","author":"J Khoshnoodi","year":"2006","unstructured":"Khoshnoodi J, Cartailler JP, Alvares K, Veis A, Hudson BG. Molecular recognition in the assembly of collagens: terminal noncollagenous domains are key recognition modules in the formation of triple helical protomers. J Biol Chem. 2006;281(50):38117\u201321. https:\/\/doi.org\/10.1074\/jbc.R600025200.","journal-title":"J Biol Chem"},{"issue":"5","key":"1623_CR18","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.ekir.2020.01.008","volume":"5","author":"M Kamura","year":"2020","unstructured":"Kamura M, Yamamura T, Omachi K, Suico MA, Nozu K, Kaseda S, et al. Trimerization and genotype-phenotype correlation of COL4A5 mutants in Alport Syndrome. Kidney Int Rep. 2020;5(5):718\u201326. https:\/\/doi.org\/10.1016\/j.ekir.2020.01.008.","journal-title":"Kidney Int Rep"},{"issue":"9","key":"1623_CR19","doi-asserted-by":"publisher","first-page":"3878","DOI":"10.1021\/ct400314y","volume":"9","author":"R Salomon-Ferrer","year":"2013","unstructured":"Salomon-Ferrer R, Gotz AW, Poole D, Le Grand S, Walker RC. Routine Microsecond Molecular Dynamics Simulations with AMBER on GPUs. 2. Explicit Solvent particle Mesh Ewald. J Chem Theory Comput. 2013;9(9):3878\u201388. https:\/\/doi.org\/10.1021\/ct400314y.","journal-title":"J Chem Theory Comput"},{"key":"1623_CR20","doi-asserted-by":"publisher","first-page":"630787","DOI":"10.3389\/fgene.2021.630787","volume":"12","author":"Y Alyafee","year":"2021","unstructured":"Alyafee Y, Al Tuwaijri A, Alam Q, Umair M, Haddad S, Alharbi M, et al. Next generation sequencing based non-invasive prenatal testing (NIPT): First Report from Saudi Arabia. Front Genet. 2021;12:630787. https:\/\/doi.org\/10.3389\/fgene.2021.630787.","journal-title":"Front Genet"},{"key":"1623_CR21","doi-asserted-by":"publisher","first-page":"1047474","DOI":"10.3389\/fgene.2022.1047474","volume":"13","author":"Y Alyafee","year":"2022","unstructured":"Alyafee Y, Al Tuwaijri A, Umair M, Alharbi M, Haddad S, Ballow M, et al. Non-invasive prenatal testing for autosomal recessive disorders: a new promising approach. Front Genet. 2022;13:1047474. https:\/\/doi.org\/10.3389\/fgene.2022.1047474.","journal-title":"Front Genet"},{"issue":"4","key":"1623_CR22","doi-asserted-by":"publisher","first-page":"461","DOI":"10.3390\/genes12040461","volume":"12","author":"Y Alyafee","year":"2021","unstructured":"Alyafee Y, Alam Q, Tuwaijri AA, Umair M, Haddad S, Alharbi M, et al. Next-generation sequencing-based Pre-Implantation Genetic Testing for Aneuploidy (PGT-A): First Report from Saudi Arabia. Genes (Basel). 2021;12(4):461. https:\/\/doi.org\/10.3390\/genes12040461.","journal-title":"Genes (Basel)"},{"issue":"10","key":"1623_CR23","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1002\/acn3.50898","volume":"6","author":"M Alfadhel","year":"2019","unstructured":"Alfadhel M, Umair M, Almuzzaini B, Alsaif S, AlMohaimeed SA, Almashary MA, et al. Targeted SLC19A3 gene sequencing of 3000 saudi newborn: a pilot study toward newborn screening. Ann Clin Transl Neurol. 2019;6(10):2097\u2013103. https:\/\/doi.org\/10.1002\/acn3.50898.","journal-title":"Ann Clin Transl Neurol"}],"container-title":["BMC Medical Genomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-023-01623-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12920-023-01623-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12920-023-01623-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T08:19:31Z","timestamp":1700295571000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedgenomics.biomedcentral.com\/articles\/10.1186\/s12920-023-01623-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,18]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1623"],"URL":"https:\/\/doi.org\/10.1186\/s12920-023-01623-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2104716\/v1","asserted-by":"object"}]},"ISSN":["1755-8794"],"issn-type":[{"value":"1755-8794","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,18]]},"assertion":[{"value":"26 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The research was carried out in adherence to the principles outlined in the Declaration of Helsinki and was granted approval by the Ethics Committee of Inner Mongolia Medical University, with the assigned ethics number YKD2019096, on March 7th, 2019. The Ethics Committee of Inner Mongolia Medical University reviewed and approved the studies that involved human participants. The participants\u2019 legal guardian\/next of kin provided written informed consent to participate in the study. Additionally, written informed consent was obtained from the individual(s) and minor(s)\u2019 legal guardian\/next of kin for the publication of any potentially identifiable images or data included in this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"192"}}